On Tuesday, Dejour Energy Inc (USA) (NYSEMKT:DEJ)’s shares inclined 2.54% to $0.125.
Dejour Energy Inc (USA) (DEJ) declared that it has received notification on June 1, 2015 from the NYSE MKT (“the Exchange”) that it has regained compliance with Section 1003(a)(iv) of the Exchange’s Company Guide as of the end of the maximum eighteen month cure period that ended on May 22, 2015. This requirement addresses a company’s ability to continue to operate as a going concern.
The Company noted that the Exchange is ongoing to actively monitor its liquidity position on an ongoing basis, counting its progress on several near term milestones communicated to the Exchange in connection with its business plan.
Dejour Energy Inc. engages in acquiring, exploring, and developing energy projects with a focus on oil and gas exploration in Canada and the United States. It holds interests in about 60,100 net acres of oil and gas leases in the Peace River Arch of northwestern British Columbia and northeastern Alberta, Canada; and the Piceance, Paradox, and Uinta Basins in the U.S. Rocky Mountains.
CA, Inc. (NASDAQ:CA)’s shares gained 1.22% to $30.17.
CA, Inc. (CA) assists drive business growth by improving the time-to-market for revenue-generating applications that depend on APIs. Results show a 97 percent time improvement to deploy apps that require integration with multiple data sets—going from 90 days to three days using CA’s API solutions. The study, “The Total Economic Impact™ of CA Technologies CA API Administration,”1 conducted by Forrester Consulting and commissioned by CA Technologies (CA), provides analysis from Forrester based on in-depth interviews with CA API Administration customers.
Consumer and employee appetite for more applications is growing and 94 percent of business executives said they faced raised pressure to release apps more quickly2. APIs are being used to assist speed app development and delivery.
CA, Inc. provides information technology (IT) administration software and solutions that assist organizations plan, develop, manage, and secure applications and IT infrastructure in the United States and internationally. The company operates through three segments: Mainframe Solutions, Enterprise Solutions, and Services.
At the end of Tuesday’s trade, xG Technology Inc (NASDAQ:XGTI)‘s shares surged 7.55% to $0.285.
xG Technology Inc (XGTI) declared it has begun collaborating with its Technology Alliance partner DirectView Holdings, Inc. ( DIRV), in beta testing of DirectView’s innovative body-worn camera solution for law enforcement agencies. xG declared its agreement to integrate xMax private mobile broadband technology with the DirectView camera on April 27, 2015.
xG and DirectView conducted initial integration and testing of one of the first-received DirectView body-worn camera units last week at xG’s central engineering facility in Sunrise, FL. Initial test results showed that DirectView’s camera hardware was easily recognized by the xMax system, and that video transmissions were seamlessly supported over the xMax network.
xG Technology, Inc. develops communications technologies for wireless networks worldwide. The company’s intellectual property is embedded in proprietary software algorithms designed to offer cognitive interference mitigation and spectrum access solutions to organizations in a various industries, counting national defense and rural broadband.
CTI BioPharma Corp (NASDAQ:CTIC), ended its Tuesday’s trading session with -1.88% loss, and closed at $2.09.
CTI BioPharma Corp (CTIC) declared that it has amended its existing loa contract with Hercules Technology Growth Capital, Inc. (Hercules). Following the amendment, Hercules agreed to provide term loans in an aggregate principal amount of up to $25.0 million under the facility, inclusive of amounts outstanding right away prior to closing of the amendment. On June 9, 2015, about $6.2 million (less fees and expenses) was funded, thereby resulting in a current outstanding principal balance under the facility of $20.0 million. The remaining $5.0 million is accessible for borrowing at CTI BioPharma’s option through June 30, 2016, subject to no event of default under the facility and the satisfaction of the following two conditions: (1) receipt by Hercules on or prior to December 31, 2015 of satisfactory evidence that CTI BioPharma has achieved full patient enrollment for the PERSIST-2 Phase III clinical trial for pacritinib and (2) receipt by Hercules on or prior to June 30, 2016 of satisfactory evidence that CTI BioPharma has achieved positive phase III data in connection with such clinical trial. In connection with the amendment, CTI BioPharma issued Hercules a warrant exercisable in whole or in part for up to 292,398 shares of common stock of CTI BioPharma at any time prior to June 9, 2020 at an initial exercise price per share of $1.71. CTI BioPharma intends to use any future proceeds from any future cash exercise of the warrant for general corporate purposes.
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
